42 patents
Utility
Immunosuppressants In Combination with Anti-igm Agents and Related Dosing
9 Nov 23
Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with an immunosuppressant and an anti-IgM agent.
Petr Ilyinskii, Takashi Kei Kishimoto
Filed: 8 Mar 23
Utility
Tolerogenic Synthetic Nanocarriers to Reduce Antibody Responses
12 Oct 23
Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Filed: 8 Dec 22
Utility
Immunosuppressant In Combination with High Affinity IL-2 Receptor Agonists and Related Dosing
12 Oct 23
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 8 Mar 23
Utility
Tolerogenic Synthetic Nanocarriers to Reduce Immune Responses to Therapeutic Proteins
12 Oct 23
Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Filed: 2 Mar 23
Utility
Tolerogenic synthetic nanocarriers for allergy therapy
10 Oct 23
Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Filed: 4 Mar 16
Utility
Tolerogenic Synthetic Nanocarriers for Allergy Therapy
5 Oct 23
Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Filed: 9 Dec 22
Utility
Tolerogenic synthetic nanocarriers
8 Aug 23
This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects.
Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
Filed: 22 Feb 16
Utility
Methods and Compositions for Attenuating Anti-viral Transfer Vector Igm Responses
11 May 23
Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and an anti-IgM agent.
Petr Ilyinskii, Takashi Kei Kishimoto
Filed: 12 Oct 22
Utility
Methods and Compositions for Inducing Autophagy
11 May 23
Provided herein are methods and compositions related to compositions comprising synthetic nanocarriers comprising an immunosuppressant.
Petr Ilyinskii, Takashi Kei Kishimoto
Filed: 14 Apr 20
Utility
Osmotic Mediated Release Synthetic Nanocarriers
4 May 23
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.
David H. Altreuter, Aaron P. Griset
Filed: 28 Jul 22
Utility
Viral Vector Dosing Protocols
4 May 23
Disclosed, at least in part, are dosings of viral vectors concomitantly with synthetic nanocarriers attached to an immunosuppressant, in combination with dosings of the synthetic nanocarriers attached to an immunosuppressant without a viral vector or further dosings of the synthetic nanocarriers attached to an immunosuppressant concomitantly with doses of the viral vector, and related compositions that provide reduced humoral immune responses and/or increased or durable transgene or nucleic acid material expression.
Takashi Kei Kishimoto
Filed: 12 Oct 22
Utility
Methods and compositions for attenuating anti-viral transfer vector immune responses
25 Apr 23
Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Takashi Kei Kishimoto
Filed: 7 Sep 15
Utility
Methods and Compositions Related to Combined Treatment with Anti-inflammatories and Synthetic Nanocarriers Comprising an Immunosuppressant
20 Apr 23
Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic.
Lloyd Johnston
Filed: 21 Jul 22
Utility
Methods and Compositions Related to Combined Treatment with Anti-inflammatories and Synthetic Nanocarriers Comprising an Immunosuppressant
6 Apr 23
Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic.
Lloyd Johnston
Filed: 30 Aug 22
Utility
Methods Providing a Therapeutic Macromolecule and Synthetic Nanocarriers Comprising Immunosuppressant Locally and Concomitantly to Reduce Both Type 1 and Type IV Hypersensitivity
2 Feb 23
Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
Roberto A. Maldonado
Filed: 9 Mar 22
Utility
Methods for Providing Polymeric Synthetic Nanocarriers for Generating Antigen-specific Tolerance Immune Responses
10 Nov 22
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods.
David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
Filed: 16 Dec 21
Utility
Synthetic Nanocarriers Comprising an Immunosuppressant In Combination with High Affinity IL-2 Receptor Agonists to Enhance Immune Tolerance
13 Oct 22
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 8 Apr 22
Utility
Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
30 Aug 22
Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic.
Lloyd Johnston
Filed: 11 Mar 18
Utility
Methods and Compositions for Reducing Immune Responses Against Immunoglobulin Proteases
5 May 22
Disclosed are methods and related compositions for administering an immunoglobulin (Ig) protease in combination with synthetic nanocarriers comprising immunosuppressants.
Takashi Kei Kishimoto
Filed: 4 Nov 21
Utility
Methods of Administering Immunosuppressants Having a Specified Pharmacodynamic Effective Life and Therapeutic Macromolecules for the Induction of Immune Tolerance
10 Mar 22
This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.
Takashi Kei Kishimoto
Filed: 24 Mar 21